Cyclobenzaprine hydrochloride and Lower respiratory tract infection - a phase IV clinical study of FDA data

Summary:

Lower respiratory tract infection is reported as a side effect among people who take Cyclobenzaprine hydrochloride (cyclobenzaprine hydrochloride), especially for people who are female, 60+ old, also take Epinephrine, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Lower respiratory tract infection when taking Cyclobenzaprine hydrochloride. It is created by eHealthMe based on reports of 7,558 people who have side effects when taking Cyclobenzaprine hydrochloride from the FDA, and is updated regularly.

What is Cyclobenzaprine hydrochloride?

Cyclobenzaprine hydrochloride has active ingredients of cyclobenzaprine hydrochloride. It is often used in muscle spasms. eHealthMe is studying from 9,351 Cyclobenzaprine hydrochloride users. Check the latest studies of Cyclobenzaprine hydrochloride.

What is Lower respiratory tract infection?

Lower respiratory tract infection is found to be associated with 1,321 drugs and 1,158 conditions by eHealthMe. Check the latest studies of Lower respiratory tract infection.

On Jul, 11, 2026

7,558 people reported to have side effects when taking Cyclobenzaprine hydrochloride.
Among them, 20 people (0.26%) have Lower respiratory tract infection.

Could Cyclobenzaprine hydrochloride cause Lower respiratory tract infection?

Among these 20 people:

What is the gender of people who have Lower respiratory tract infection when taking Cyclobenzaprine hydrochloride? *

female: 64.71 %
male: 35.29 %

What is the age of people who have Lower respiratory tract infection when taking Cyclobenzaprine hydrochloride? *

What are other drugs people take besides Cyclobenzaprine hydrochloride? *

What are other side effects people have besides Lower respiratory tract infection? *

Sinusitis (inflammation of sinus): 12 people, 60.00%
Dyspnea (difficult or laboured breathing): 10 people, 50.00%
Chest Pain: 9 people, 45.00%
Nausea (feeling of having an urge to vomit): 9 people, 45.00%
Nausea And Vomiting: 8 people, 40.00%
Headache (pain in head): 8 people, 40.00%
Pneumonia: 7 people, 35.00%
Weakness: 7 people, 35.00%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 7 people, 35.00%
Fever: 7 people, 35.00%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 7 people, 35.00%
Primary Immunodeficiency Syndrome: 5 people, 25.00%
Hypersensitivity: 5 people, 25.00%
Multifocal Motor Neuropathy (a progressively worsening condition where muscles in the extremities gradually weaken): 2 people, 10.00%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 2 people, 10.00%
Toxic Neuropathy (nerve damage caused by toxic (harmful) substances): 2 people, 10.00%
Multiple Myeloma (cancer of the plasma cells): 2 people, 10.00%
Ovarian Cancer (cancer of ovary): 2 people, 10.00%
Monoclonal Gammopathy: 1 person, 5.00%
Insomnia (sleeplessness): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Cyclobenzaprine hydrochloride and have Lower respiratory tract infection?

- Check whether Lower respiratory tract infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cyclobenzaprine hydrochloride:

Cyclobenzaprine hydrochloride (9,351 reports)

Browse all side effects of Cyclobenzaprine hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lower respiratory tract infection:

Lower respiratory tract infection (1,321 drugs)

Browse all the conditions that are associated with Lower respiratory tract infection:

Lower respiratory tract infection (1,158 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cyclobenzaprine hydrochloride (the active ingredients of Cyclobenzaprine hydrochloride) and Cyclobenzaprine hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.